Orris

Explain: Deleterious cardiac remodeling due to catecholamines, angiotensin ii and aldosterone in heart failure with reduced ejection fraction

Reading File
Finding Sources
Finding Sources
Searching PubMed

"heart failure"[MeSH Terms] AND "cardiac remodeling"[MeSH Terms]

Searching the Web

HFrEF neurohormonal activation catecholamines angiotensin II aldosterone cardiac remodeling authoritative review

Reading File
Reading File
Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC5286912

In heart failure with reduced ejection fraction (HFrEF), impaired LV systolic function lowers cardiac output and effective arterial perfusion. This activates the:
  • Sympathetic nervous system (SNS), causing persistent catecholamine release, mainly norepinephrine
  • Renin-angiotensin-aldosterone system (RAAS), causing angiotensin II and aldosterone excess
These mechanisms initially support blood pressure and organ perfusion, but chronic activation drives a self-perpetuating cycle of adverse LV remodeling: ventricular dilatation, hypertrophy, fibrosis, worsening contractility, and arrhythmias.

1. Catecholamines: chronic sympathetic stimulation

Early SNS activation raises heart rate, contractility, and peripheral vasoconstriction. Chronically, elevated norepinephrine becomes toxic to the myocardium.
Mechanisms of adverse remodeling
  • β1-receptor overstimulation increases cAMP and intracellular calcium. Persistent calcium loading causes myocyte injury, apoptosis or necrosis, and impaired excitation-contraction coupling.
  • β-adrenergic receptor downregulation and desensitization develops. The failing heart then becomes less responsive to sympathetic stimulation and loses contractile reserve.
  • Tachycardia and increased wall stress increase myocardial oxygen demand while shortening diastole and potentially reducing coronary perfusion reserve. This worsens ischemia and energy depletion.
  • Catecholamines promote hypertrophy, oxidative stress, and activation of pro-fibrotic pathways.
  • They increase susceptibility to ventricular arrhythmias through calcium overload, triggered activity, and myocardial scar/fibrosis.
Thus, SNS activation changes from short-term support to a cause of myocyte loss, fibrosis, chamber dilatation, and progressive systolic dysfunction. The textbook describes augmented catecholamine exposure as causing myocyte death, fibrosis, and adverse remodeling. Fuster and Hurst's The Heart, p. 1575. It also notes calcium-overload toxicity, receptor suppression, increased oxygen consumption, reduced mechanical efficiency, LV hypertrophy, and arrhythmias. Textbook of Family Medicine 9e, p. 689.

2. Angiotensin II: afterload, volume load, and direct myocardial injury

Reduced renal perfusion and increased sympathetic tone stimulate renin release, producing angiotensin II (Ang II).
Hemodynamic effects
  • Potent arteriolar vasoconstriction raises systemic vascular resistance and therefore afterload. A weak LV must eject against higher pressure, reducing stroke volume and increasing wall stress.
  • It promotes renal sodium retention directly and stimulates thirst and vasopressin release, contributing to fluid retention.
  • It stimulates adrenal secretion of aldosterone.
Direct cardiac effects
Through AT1-receptor signaling, Ang II promotes:
  • Cardiomyocyte hypertrophy
  • Apoptosis and myocyte loss
  • Reactive oxygen species generation and inflammatory signaling
  • Fibroblast activation, collagen deposition, and interstitial/perivascular fibrosis
  • Adverse extracellular-matrix remodeling
The result is a ventricle that becomes larger, more spherical, and less efficient. Fibrosis makes it stiff and electrically heterogeneous, adding diastolic dysfunction and arrhythmia risk to systolic failure.
Ang II also potentiates the SNS by increasing norepinephrine release and reducing its reuptake, further reinforcing the harmful neurohormonal cycle. In HFrEF, evidence supports neurohormones as mediators, not merely markers, of progression because levels achieved in HF can produce LV dysfunction/remodeling and blocking these systems improves outcomes, as summarized in this NIH review.

3. Aldosterone: sodium retention and myocardial fibrosis

Aldosterone is released chiefly in response to Ang II. Its renal effect is increased sodium reabsorption in the distal nephron, with water retention.
Hemodynamic consequences
  • Expansion of intravascular volume increases venous return and preload
  • Higher LV end-diastolic volume and pressure increase wall tension
  • Pulmonary and systemic congestion develop
  • Recurrent volume overload accelerates ventricular dilatation
Direct tissue effects
Aldosterone is not only a renal hormone. In the presence of high salt intake and chronic neurohormonal activation, it contributes to:
  • Cardiac fibroblast activation and excess collagen synthesis
  • Interstitial and perivascular fibrosis
  • Endothelial dysfunction and vascular inflammation
  • Oxidative stress
  • Potassium and magnesium loss, which can increase arrhythmia risk
  • Impaired ventricular compliance and diastolic filling
Aldosterone can remain elevated despite ACE inhibitor or ARB therapy, termed aldosterone escape, explaining the additional benefit of mineralocorticoid receptor antagonists in suitable patients. Textbook of Family Medicine 9e, p. 689.

The vicious cycle

LV systolic dysfunction
        ↓
Reduced cardiac output / effective arterial filling
        ↓
SNS activation + RAAS activation
        ↓
Catecholamines + Ang II + aldosterone
        ↓
Vasoconstriction, sodium/water retention, tachycardia,
hypertrophy, myocyte injury, apoptosis, and fibrosis
        ↓
Higher preload and afterload + worsening LV geometry
        ↓
Further reduction in ejection fraction and HF progression

Why this matters therapeutically

The benefit of HFrEF disease-modifying treatment is closely tied to interrupting this cycle:
  • Evidence-based beta-blockers limit catecholamine toxicity, slow heart rate, reduce arrhythmias, and promote reverse remodeling.
  • ACE inhibitors, ARBs, or ARNIs reduce Ang II-related vasoconstriction, fluid retention, hypertrophy, apoptosis, and fibrosis.
  • Mineralocorticoid receptor antagonists counter aldosterone-mediated sodium retention and fibrosis.
  • SGLT2 inhibitors also improve HF outcomes and may support reverse remodeling. A 2024 systematic review and meta-analysis reported favorable effects on left cardiac remodeling in HFrEF (PMID: 38235936).
In brief: catecholamines damage myocytes through chronic adrenergic and calcium stress; Ang II raises afterload and directly promotes hypertrophy, apoptosis, and fibrosis; aldosterone causes volume overload and fibrosis. Together they progressively distort LV structure and worsen HFrEF.
This is a shared conversation. Sign in to Orris to start your own chat.